Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intratumoral Administration of DTA-H19 n Patients With Unresectable Pancreatic Cancer.

Trial Profile

Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intratumoral Administration of DTA-H19 n Patients With Unresectable Pancreatic Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2013

At a glance

  • Drugs BC 819 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Nov 2010 Results reported in a Tikcro (shareholders in BioCancell Therapeutics) media release.
    • 02 Nov 2010 Results reported in a BioCancell media release.
    • 07 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top